Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Weekly Paclitaxel in Recurrent Gynecologic Cancers
NCT02788708Phase 1Completed
- Start
- May 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC) and 1 more. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started May 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02788708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788708.